Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Maqola

Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16

Lilit GhukasyanEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, RussiaGeorge S. KrasnovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, RussiaО. В. МуравенкоEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, RussiaA. Yu. IkonnikovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, RussiaR. A. YurasovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, RussiaЛ. В. БайдунRussian Children’s Clinical Hospital, 119117, Moscow, RussiaSandugash IbragimovaScientific Research Institute of Hematology and Blood Transfusion, 100185, Tashkent, UzbekistanТ. В. НаседкинаDmitry Rogachev National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, 119117, Moscow, Russia
Molecular Biologyjournal2020en
ABI

Annotatsiya

Certain subtypes of acute myeloid leukemia occur as a result of the cooperation of several events these are, the formation of fusion genes as a result of chromosomal rearrangements, which leads to the disruption of cell differentiation, and the emergence of mutations that enhance cellular proliferation by activating intracellular signaling pathways. High-throughput sequencing methods reveal characteristic mutation spectra in leukemia associated with different chromosomal disorders. However, the role of mutation events in malignant cell transformation processes remains obscure. We searched for driver mutation events in leukemic cells containing the chimeric CBFB-MYH11 gene, which results from inversion of chromosome 16. Using target enrichment, the coding regions of 84 genes in genomes of 12 children with acute myeloid leukemia with inv(16) were investigated. Somatic mutations have been found in the genes of the proteins of intracellular signaling cascades mediated by receptor tyrosine kinases, such as KIT (41%), NRAS (25%), KRAS (17%), and FLT3 (8.3%). Comparative analysis of samples at the time of diagnosis and during remission was used to assess the role of mutations in the pathogenesis of the disease. Previously undescribed mutations in the KDM6A, NOTCH1, and IDH1 genes, which may be involved in leukemogenesis processes have been identified.

Hali tarjima qilinmagan

Mavzular

Identifikatorlar

Iqtiboslar va manbalar

Koʻrsatkichlar — AkademScholar · Tez orada